Wordt geladen...
Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database
BACKGROUND: Biological therapies (BTs) including infliximab (IFX), adalimumab (ADL), secukinumab (SCK) and ustekinumab (UST) are approved in Japan for the treatment of psoriasis. Although the persistence rates and medical costs of BTs treatment have been investigated in multiple foreign studies in r...
Bewaard in:
| Gepubliceerd in: | BMC Dermatol |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6042444/ https://ncbi.nlm.nih.gov/pubmed/29996929 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12895-018-0074-0 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|